FDA expands approved use of bosutinib in CML

Print Friendly, PDF & Email


CML cells
Image by Difu Wu
The US Food and Drug Administration (FDA) has expanded the approved indication for bosutinib (BOSULIF®). The tyrosine kinase inhibitor (TKI) is now approved to treat adults with newly diagnosed, chronic phase, Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Bosutinib has accelerated approval for this indication. The approval was... [Read Article]
Print Friendly, PDF & Email

Natural selection opportunities tied to cancer rates

Print Friendly, PDF & Email


Cancer patient receiving chemotherapy
Photo by Rhoda Baer
Countries with the lowest opportunities for natural selection have higher cancer rates than countries with the highest opportunities for natural selection, according to a study published in Evolutionary Applications. Researchers said this is because modern medicine is enabling people to survive cancers, and their genetic... [Read Article]
Print Friendly, PDF & Email